Eosinophil Subpopulations in Eosinophilic-associated Diseases

Introduction Eosinophils (Eos) play a crucial role in both normal physiological functions and various pathological conditions. They are primarily recognized for their involvement in immune defense against infections, including parasitic, bacterial, and viral infections, as well as in cancer surveillance. However, they are also key contributors to eosinophil-associated diseases (EADs) such as bronchial asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). Recent research has revealed that eosinophils exist in distinct subpopulations with unique phenotypic characteristics and functions. These subpopulations, referred to as resident eosinophils (rEos) and inflammatory eosinophils (iEos), have been primarily studied in healthy tissues and in conditions like severe eosinophilic asthma (SEA) and CRSwNP. While rEos are believed to contribute to tissue homeostasis and immune regulation, iEos are associated with inflammatory responses. Studies in mouse models have demonstrated the presence of these subpopulations in lung tissue, but their role in human disease remains less understood. Although there is emerging evidence suggesting the presence of these eosinophil subsets in human peripheral blood and nasal polyp tissue, they have not been fully characterized in other EADs such as EGPA and HES. Understanding whether these subpopulations exist in these diseases and how they are influenced by type 2 cytokines could provide valuable insights into disease mechanisms. Furthermore, as eosinophil-targeted therapies such as Mepolizumab (an anti-IL-5 monoclonal antibody) are already in clinical use, clarifying their specific effects on these eosinophil subsets could help optimize treatment strategies. Study Rationale and Objectives This study aims to expand on previous findings by investigating whether distinct eosinophil subpopulations exist in EGPA and HES patients. Additionally, the study seeks to analyze how type 2 cytokines influence the differentiation and function of these eosinophil subsets. A key aspect of this research is assessing the effect of Mepolizumab on rEos and iEos, particularly whether it selectively targets inflammatory eosinophils without affecting homeostatic eosinophils. The primary objectives of this study include: Confirming the presence of two distinct eosinophil subpopulations in EGPA and HES. Investigating the impact of type 2 cytokines on eosinophil plasticity and function. Secondary objectives involve comparing iEos proportions across different eosinophilic diseases and analyzing their correlation with disease severity. Additionally, the study will explore how in vitro exposure to Mepolizumab affects the balance between rEos and iEos in EGPA and HES patients. Study Design The study will involve patients diagnosed with severe eosinophilic asthma (SEA), EGPA, and HES, along with a control group of healthy donors. Blood samples will be collected and analyzed using flow cytometry to characterize eosinophil subpopulations. In vitro experiments will assess the effects of type 2 cytokines (such as IL-5, IL-3, GM-CSF, IL-4, and IL-13) on these eosinophil subsets, as well as the impact of Mepolizumab. Subject Selection and Eligibility Criteria Participants must be between 18 and 75 years old and diagnosed with SEA, EGPA, or HES. Healthy donors within the same age range will be included as controls. Individuals with chronic lung diseases (such as COPD), other immune-mediated inflammatory conditions, recent infections, parasitic infestations, or immunosuppressive treatments will be excluded to ensure a clear focus on eosinophilic-driven inflammation. Ethical Considerations and Study Management This study will adhere to ethical guidelines outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) regulations. Informed consent will be obtained from all participants, ensuring they fully understand the study's purpose and procedures. Ethical approval will be secured from the relevant institutional review boards before the study commences. Biological samples will not be stored beyond their immediate use, and strict chain-of-custody procedures will be followed. If a participant withdraws consent, their samples will be immediately destroyed unless they have already been analyzed. Statistical Analysis and Expected Outcomes This is an exploratory pilot study, and an estimated 135 patients (80 SEA, 30 EGPA, 25 HES) and 25 healthy donors will be recruited. Statistical methods, including Mann-Whitney U tests, ANOVA, and Spearman correlation tests, will be used to analyze the data. The primary focus will be to determine the proportion of iEos and rEos in different disease states and evaluate their response to cytokine stimulation and Mepolizumab treatment. If successful, this study could lead to a deeper understanding of eosinophil biology and its implications in eosinophilic disorders. More importantly, it could refine therapeutic strategies by identifying whether Mepolizumab specifically targets inflammatory eosinophils while preserving homeostatic ones, ultimately leading to more personalized treatment approaches for patients with EADs.